You have printed or saved this information from www.HorizonNB.ca, the website for the Horizon Health Network

Facebook Icon LinkedIn Icon Twitter Icon Icon Icon
Print this page

Cancer Research

Cancer Research at Horizon

ANY CANCER

SC.27: Living with Cancer in the Time of COVID-19: A cohort study of the impact of COVID-19 pandemic on cancer patients during treatment and survivors.

The purpose of the study is to collect information regarding the experience that people living with cancer and cancer survivors have during this COVID-19 pandemic to understand how these experiences could be improved. The study is set to find out: the effects on your quality of life, stress, relationships, and your health care.

  • Condition: Any cancer
  • Website: https://covid19livingwithcancer.ca/
  • Location: Saint John Regional Hospital
  • Horizon Principal Investigator: Dr. Margot Burnell
  • To participate, call the research coordinator at: 506-648-6890 and refer to study file #100954

STAY STRONG: Evaluation of a community-based, 12 week exercise program for cancer recovery

The purpose of the study is to create a research database for interested participants of the Stay Strong Cancer Recovery Program. This database is being created to monitor clinical outcomes and for future clinical research.

  • Condition: Any cancer
  • Location: Saint John Regional Hospital
  • Horizon Principal Investigator: Dr. Margot Burnell
  • To participate, call the research coordinator at: 506-648-6890 and refer to study file #100228

PMT Registry: Personalize My Treatment

The Personalize My Treatment is a collection of longitudinal clinical data as well as molecular data from cancer patients across different parts of Canada, which serves as a comprehensive biological and data resource.

The goals of the PMT registry are: to increase scientific knowledge of cancer through access to your health records, otherwise known as real-world data, and biospecimens, and to increase the number of precision oncology trials in Canada, and to match patients in the registry to these trials.

  • Condition: Any cancer
  • Study ID: NCT02355171
  • Sponsor: Exactis Innovation
  • Location: The Moncton Hospital
  • Horizon Principal Investigator: Dr. Mahmoud Abdelsalam
  • To participate, call the research coordinator at: 506-857-5756 and refer to study file #10123

KEYLYNK-007: Olaparib in combination with pembrolizumab in people with homologous recombination repair mutation (HRRm) and/or homologous recombination deficiency (HRD) positive cancer

The purpose of this study is to assess the efficacy and safety of treatment with olaparib (MK-7339) in combination with pembrolizumab (MK-3475) in adults with previously treated, advanced (metastatic and/or unresectable) Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-positive solid tumors.

  • Condition: Solid tumours
  • Study ID:NCT04123366
  • Sponsor: Merck Sharp & Dohme, Corp.
  • Location: The Moncton Hospital
  • Horizon Principal Investigator: Dr. Mahmoud Abdelsalam
  • To participate, call the research coordinator at: 506-857-5836 and refer to study file #100631

BLADDER CANCER

A Trial of Perioperative Pembrolizumab Alone or Together with Enfortumab Vedotin for Cisplatin-ineligible Participants  with Muscle-Invasive Bladder Cancer (MIBC)

The purpose of this study is to:

  • See if pembrolizumab with and without enfortumab vedotin, given before and after surgery is more effective than surgery alone in patients with muscle-invasive bladder cancer (MIBC) including patients with T1N1M0 or Stage IIIA bladder cancer and are not eligible to receive cisplatin treatment. This will be measured by tissue samples that are taken during surgery as well as imaging performed at different time points in the study.
  • Test the safety of the, pembrolizumab, with and without enfortumab vedotin given before and after surgery.
  • See how well your body handles pembrolizumab, with and without enfortumab vedotin given before and after surgery.
  • See if pembrolizumab, with and without enfortumab vedotin, given before and aftersurgery, compared to surgery alone, helps patients have a better quality of life.
  • See if pembrolizumab, with and without enfortumab vedotin,helps patients live longer.
  • Condition: High-risk, non-muscle-invasive bladder cancer
  • Study ID: NCT03711032
  • Sponsor: Merck Sharp & Dohme, Corp.
  • Location: The Moncton Hospital
  • Horizon Principal Investigator: Dr. Troy Sitland
  • To participate, call the research coordinator at: 506-857-5756 and refer to study file #10145

Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Cisplatin-ineligible Participants With Muscle-invasive Bladder Cancer

This is a global, randomized phase III study to evaluate perioperative pembrolizumab with radical cystectomy + pelvic lymph node dissection (RC+PLND) versus RC+PLND alone in cisplatin-ineligible patients with muscle-invasive bladder cancer (MIBC).

  • Condition: Muscle-invasive bladder cancer
  • Study ID: NCT03924895
  • Sponsor: Merck Sharp & Dohme, Corp.
  • Location: The Moncton Hospital
  • Horizon Principal Investigator: Dr. Mahmoud Abdelsalam
  • To participate, call the research coordinator at: 506-857-5756 and refer to study file #100313

BREAST CANCER

Randomized Phase III Trial Evaluating The Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer

The purpose of this study is to see if losing weight may help prevent breast cancer from coming back (recurring). This study will help to understand whether weight loss programs should be a part of breast cancer treatment. To do this, participants in this study will receive either a Health Education program or a Health Education program with a 2-year weight loss program.  

  • Condition: Breast cancer
  • Study ID: NCT02750826
  • Sponsor: Canadian Cancer Trials Group
  • Locations:
    • The Moncton Hospital
      • Horizon Principal Investigator: Dr. Maged Salem
      • To participate, call the research coordinator at: 506-870-2832 and refer to study file #10067

MAC.24: Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer

The purpose of this study is to compare the effects on you and your breast cancer of receiving one year of therapy with a new drug, MK‑3475 (pembrolizumab), compared to usual approach to treat this disease.

  • Condition: Triple-negative breast cancer
  • Study ID: NCT02954874
  • Sponsor: Canadian Cancer Trials Group
    • Locations:
      • Saint John Regional Hospital
        • Horizon Principal Investigator: Dr. Margot Burnell
        • To participate, call the research coordinator at: 506-648-6890 and refer to study file #100494

TAILOR RT: Regional Radiotherapy in Biomarker Low Risk Node Positive Breast Cancer

The purpose of this study is to compare the effects on low risk breast cancer receiving usual care that includes regional radiation therapy, with receiving no regional radiation therapy. Researchers want to see if not giving this type of radiation treatment works as well at preventing breast cancer from coming back.

  • Condition: Breast cancer
  • Study ID: NCT03488693
  • Sponsor: Canadian Cancer Trials Group
  • Location: Saint John Regional Hospital
  • Horizon Principal Investigator: Dr. Farah Naz
  • To participate, call the research coordinator at: 506-648-6890 and refer to study file #100089

PICOMOLE BREAST: Analysis of volatile chemicals in the breath of breast cancer patients using infrared spectroscopy

The purpose of this study is to sample and analyze the volatile organic compounds (VOCs) in the breath of breast cancer patients before the start of treatment, and "healthy" individuals without breast cancer at three hospital sites: (1) Saint John Regional Hospital, and (2) Moncton Hospital. The breath sample analysis will allow for the identification of patterns of VOCs in patients with breast cancer compared to "healthy" breath profiles using infrared spectroscopy. The researchers think that the profile of volatile chemicals in the breath of breast cancer patients might be different from those individuals without breast cancer.

  • Condition: Breast cancer
  • Sponsor: Picomole, Inc.
  • Locations:
    • Saint John Regional Hospital
      • Horizon Principal Investigator: Dr. Farah Naz
      • To participate, call the research coordinator at: 506-648-6890 and refer to study file #100559
      • The Moncton Hospital
        • Horizon Principal Investigator: Dr. Maged Salem
        • To participate, call the research coordinator at: 506‑857‑5267 and refer to study file #100559

COLON & COLORECTAL CANCER

Health Education Materials With/Out a Physical Activity Program for Patients Who Have Undergone Treatment for High-Risk Stage II or Stage III Colon Cancer

The purpose of this study is to find out whether it is better to take part in a structured physical activity program designed to increase the amount of physical activity you do in addition to receiving general health education materials or better to receive general health education materials only after surgery and chemotherapy for colon cancer.

  • Condition: Colorectal cancer
  • Study ID: NCT00819208
  • Sponsor: Canadian Cancer Trials Group
    • Locations:
      • Saint John Regional Hospital
        • Horizon Principal Investigator: Dr. Anthony Reiman
        • To participate, call the research coordinator at: 506-648-6890 and refer to study file #10104

CO.27: A phase III, randomised, international trial comparing mFOLFIRINOX triplet chemotherapy to mFOLFOX for high risk stage III colon cancer in adjuvant setting

The trial is a phase III, multicenter, open-labeled randomized trial comparing the association 5-fluorouracil (5-FU), folinic acid, irinotecan and oxaliplatin (mFOLFIRINOX) versus oxaliplatin, folinic acid, 5-FU (mFOLFOX 6) chemotherapy protocols in patients with high-risk stage III colon cancer in the adjuvant setting.

  • Condition: Colon cancer
  • Study ID:NCT02967289
  • Sponsor: UNICANCER
  • Locations:
    • Saint John Regional Hospital
      • Horizon Principal Investigator: Dr. Samantha Gray
      • To participate, call the research coordinator at: 506-648-6890 and refer to study file #10206

COBRA:Phase II/III study of Circulating tumor DNA as a predictive BiomaRker in Adjuvant chemotherapy in stage IIA colon cancer

The purpose of this study is to determine whether to recommend chemotherapy or no further treatment after surgery for an early stage colon cancer, by taking a blood sample and testing for the presence of circulating tumour DNA (ctDNA).

  • Condition: Colon cancer
  • Study ID: NCT04068103
  • Sponsor: NRG Oncology
  • Location: Saint John Regional Hospital
  • Horizon Principal Investigator: Dr. Samantha Gray
  • To participate, call the research coordinator at: 506-648-6890 and refer to study file #100950

A Phase 3 Randomized, Open-label Study to Evaluate the Efficacy and Safety of Olaparib Alone or in Combination with Bevacizumab Compared to Bevacizumab With 5-FU in Participants with Unresectable or Metastatic Colorectal Cancer Who Have not Progressed Following First-line Induction of FOLFOX With Bevacizumab (LYNK-003).

The purpose of this study is to:

  • Find out whether the following combinations of study drugs when taken after treatment with chemotherapy (FOLFOX and bevacizumab) delay your cancer from returning and help you live longer:
    • Olaparib and bevacizumab taken together compared with 5-Flurouracil (5FU) and bevacizumab taken together
    • Olaparib alone compared with 5-FU and bevacizumab taken together
  • Test the safety of the study drugs and see how well your body handles olaparib alone or olaparib and bevacizumab when taken together.
  • See if the study drug helps patients live longer
  • Condition: Metastatic colorectal cancer
  • Study ID: NCT04456699
  • Sponsor: Merck Sharp & Dohme Corp.
  • Locations:
    • The Moncton Hospital
      • Horizon Principal Investigator: Dr. Mahmoud Abdelsalam
      • To participate, call the research coordinator at: 506-870-2832 and refer to study file #100922

GASTROINTESTINAL CANCER

SPOTLIGHT: A Phase 3, Global, Multi-Center, Double-Blind, Randomized, Efficacy Study of Zolbetuximab (IMAB362) Plus mFOLFOX6 Compared with Placebo Plus mFOLFOX6 as First-line Treatment of Subjects with Claudin (CLDN)18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

The purpose of this study is to see if study drug, called zolbetuximab (IMAB362), is both safe and effective in combination with the chemotherapy regimen mFOLFOX6 for locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) cancer. mFOLFOX6 is a combination of medications currently approved for the treatment of gastric and GEJ cancer. The study drug zolbetuximab targets a gastric cancer specific protein to help treat gastric cancer. Zolbetuximab is an investigational drug that is not currently an approved product.

  • Condition: Unresectable or metastatic gastric / gastroesophageal junction (GEJ) cancer
  • Study ID: NCT03504397
  • Sponsor: Astellas Pharma Global Development, Inc.
  • Location: Saint John Regional Hospital
  • Horizon Principal Investigator: Dr. Samantha Gray
  • To participate, call the research coordinator at: 506-648-6890 and refer to study file #100068

HEMATOLOGICAL CANCERS

DEVOTE: Study to Describe the Management and the Use of Healthcare Resources in Patients With Chronic Lymphocytic Leukemia (CLL) Initiating Venetoclax in Routine Clinical Practice

A study to assess the real-life management and use of healthcare resources during the initiation of venetoclax in combination with rituximab is indicated for the treatment of adult participants with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy; or, venetoclax in participants with CLL with the deletion of the short arm of chromosome 17 (del[17p]) who have received at least 1 prior therapy or participants with CLL without del(17p) who have received at least 1 prior therapy and for whom there are no other available treatment options.

  • Condition: Chronic lymphocytic leukemia
  • Study ID: NCT03310190
  • Sponsor: AbbVie
  • Location: The Moncton Hospital
  • Horizon Principal Investigator: Dr. Nizar Abdel Samad
  • To participate, call the research coordinator at: 506-870-2892 and refer to study file #10058
A Multicenter, Randomized, Double-blind, Placebo-Controlled Phase 3 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Rituximab versus Placebo in Combination with Rituximab in Treatment Naïve Subjects with Follicular Lymphoma

Pharmacyclics LLC (Sponsor) is studying ibrutinib in combination with rituximab in participants with follicular lymphoma. You are invited to participate in this study to find out:

  • If and how well the study medications control your cancer
  • Whether special blood tests can predict how effective the study medications will be for you
  • How your cancer cells respond to the study medications
  • The side effects of the study medications
  • How long the study medications stay in your blood
  • Condition: Follicular lymphoma
  • Study ID: NCT02947347
  • Sponsor: Pharmacyclics LLC
  • Location: The Moncton Hospital
  • Horizon Principal Investigator: Dr. Nizar Abdel Samad
  • To participate, call the research coordinator at: 506-857-5067 and refer to study file #10169
ITHACA: A Phase 3 randomized, open label, multicenter study of isatuximab (SAR650984) in combination with lenalidomide and dexamethasone versus lenalidomide and dexamethasone in patients with high-risk smoldering multiple myeloma

Safety run in part: The purpose of this part is to confirm isatuximab (SAR650984) dose and whether isatuximab in combination with lenalidomide and dexamethasone (ILd) can be used in the randomized Phase 3 part.

Randomized Phase 3 study: The purpose of the study is to evaluate the clinical benefit and the possible risks of isatuximab (SAR650984) in combination with lenalidomide, and dexamethasone in the ILd treatment arm (also called experimental arm) compared to lenalidomide in combination with dexamethasone in the Ld treatment arm (also called control arm) in treatment of your disease.

  • Condition: Plasma cell myeloma
  • Study ID: NCT04270409
  • Sponsor: Sanofi
  • Location: The Moncton Hospital
  • Horizon Principal Investigator: Dr. Maude Landry
  • To participate, call the research coordinator at: 506-870-2832 and refer to study file #100935

M4: Multiple Myeloma Molecular Monitoring Study

The investigators will track 250 multiple myeloma patients across Canada over time, using new lab tests to evaluate their blood and bone marrow, as they receive standard of care treatment. The main hypothesis is that these tests will allow clinicians to better diagnose and manage multiple myeloma, improving patients' quality of life overall.

  • Condition: Multiple myeloma
  • Study ID: NCT03421132
  • Sponsor: Investigator-initiated
  • Location: Saint John Regional Hospital
  • Horizon Principal Investigator: Dr. Anthony Reiman
  • To participate, call the research coordinator at: 506-648-6902 and refer to study file #10204

WINNIPEG (CMRG 006): A phase 2A multi centre, open label, pilot study of pembrolizumab added to the standard first-line therapy of cyclophosphamide, bortezomib and dexamethasone (CyBorD) in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplantation

The purpose of this study is to test the safety and tolerability of pembrolizumab when it is administered with CyBorD as a first-line therapy for patients that did not achieve a very good partial response (VGPR) or better and do not qualify for a transplant.

  • Condition: Multiple myeloma
  • Study ID: NCT04258683
  • Sponsor: Canadian Myeloma Research Group
  • Location: The Moncton Hospital
  • Horizon Principal Investigator: Dr. Nizar Abdel Samad
  • To participate, call the research coordinator at: 506-857-5756 and refer to study file #100930

KIDNEY CANCER

CheckMate-914 (CA209-914): A Phase 3 Randomized, Double-Blind Study of Nivolumab Monotherapy or Nivolumab Combined with Ipilimumab vs Placebo in Participants with Localized Renal Cell Carcinoma Who Underwent Radical or Partial Nephrectomy and Who Are at High Risk of Relapse

The purpose of this study is to test the effectiveness (how well the drug works), safety, and tolerability of an investigational drug combination of nivolumab (also known as BMS-936558) and ipilimumab (also known as BMS-734016) and nivolumab (also known as BMS-936558) monotherapy in people with localized kidney cancer that have had their tumors completely removed but are at risk of having their cancer return.

  • Condition: Renal cell carcinoma
  • Study ID: NCT03138512
  • Sponsor: Bristol-Myers Squibb
  • Location: Saint John Regional Hospital
  • Horizon Principal Investigator: Dr. Samantha Gray
  • To participate, call the research coordinator at: 506-648-6890 and refer to study file #10089

LUNG CANCER

CANOPY-A: A Study of Efficacy and Safety of Canakinumab as Adjuvant Therapy in Adult Subjects With Stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) Completely Resected Non-small Cell Lung Cancer

The purpose of the study is to find out if the drug canakinumab is safe and has beneficial effects in reducing the risk of cancer reappearance in people with NSCLC who have completed the standard of care adjuvant treatment. The standard of care adjuvant treatment includes complete surgical removal of the primary cancer, followed by chemotherapy (cisplatin based), radiation therapy (if applicable) followed by monitoring for disease reappearance.

  • Condition: Non-small cell lung cancer
  • Study ID: NCT03447769
  • Sponsor: Novartis Pharmaceuticals
  • Location: The Moncton Hospital
  • Horizon Principal Investigator: Dr. Mahmoud Abdelsalam
  • To participate, call the research coordinator at: 506-857-5756 and refer to study file #100630

A Randomized Phase 3 Study of Sitravatinib in Combination with Nivolumab Versus Docetaxel in Patient with Advanced Non-Squamous Non-Small Cell Lung Cancer with Disease Progression On or After Platinum-Based Chemotherapy and Checkpoint Inhibitor Therapy (SAPPHIRE)

This study will compare the effectiveness of sitravatinib in combination with nivolumab versus docetaxel in patients with non-small cell lung cancer who have previously had progression on or after chemotherapy and immunotherapy. 

  • Condition: Metastatic non-squamous non-small cell lung cancer
  • Study ID: NCT03906071
  • Sponsor: Mirati Therapeutics Inc.
    • Locations:
      • The Moncton Hospital
        • Horizon Principal Investigator: Dr. Mahmoud Abdelsalam
        • To participate, call the research coordinator at: 506-870-2832 and refer to study file #100941
      • Saint John Regional Hospital
        • Horizon Principal Investigator: Dr. Anthony Reiman
        • To participate, call the research coordinator at: 506-648-6890 and refer to study file #101033

M7824 With cCRT in Unresectable Stage III Non-small Cell Lung Cancer (NSCLC)

The purpose of this study is to compare two treatments for patients with unresectable Stage III non-small cell lung cancer (NSCLC), the type of cancer you have.

  • Chemoradiation (chemotherapy and radiation therapy administered together) plus the study drug M7824, followed by the study drug M7824
  • Chemoradiation (chemotherapy and radiation therapy administered together) plus an inactive placebo, followed by the comparator drug duralumin. Durvalumab is an approved treatment for unresectable Stage III NSCLC. 

This study will look at how safe chemotherapy and radiation plus the study drug M7824 is ("safety") and how well this treatment may work ("efficacy").

  • Condition: Non-small cell lung cancer
  • Study ID: NCT03840902
  • Sponsor: EMD Serono Research & Development Institute Inc.
  • Location: Saint John Regional Hospital
  • Horizon Principal Investigator: Dr. Anthony Reiman
  • To participate, call the research coordinator at: 506-648-6890 and refer to study file #101033

MERMAID-1: Phase III Study to Determine the Efficacy of Durvalumab in Combination With Chemotherapy in Completely Resected Stage II-III Non-small Cell Lung Cancer (NSCLC)

The current standard of care for some non-small cell lung cancer (NSCLC_ patients who complete surgery is to go on to receive chemotherapy to reduce the risk that the cancer may come back (even if the surgery to remove the tumor was successful). Unfortunately, there is currently no way for doctors to identify which patients have a higher risk of their cancer coming back and would benefit from additional treatment after surgery. This study is aimed at finding patients who have small amounts of cancer DNA in their blood (called circulating tumour DNA or ctDNA) after surgery. This may indicate that you have minimal residual disease (MRD), meaning that even after surgery, there are still some remaining cancer cells releasing cancer DNA into your bloodstream. MRD after surgery may mean that the risk of cancer coming back is higher, which is why we would like to give additional treatment after your tumour has been removed. 

  • Condition: Non-small cell lung cancer
  • Study ID: NCT04385368
  • Sponsor: AstraZeneca
  • Location: Saint John Regional Hospital
  • Horizon Principal Investigator: Dr. Anthony Reiman
  • To participate, call the research coordinator at: 506-648-6890 and refer to study file #101035

KEYNOTE-867: A placebo-controlled study of stereotactic body radiotherapy (SBRT) with or without pembrolizumab (MK-3475) in participants with medically inoperable stages I or IIA non-small cell lung cancer (NSCLC)

The purpose of this study is to:

  • See if pembrolizumab (MK-3475) taken with Stereotactic Body Radiotherapy (SBRT) is more effective in delaying return of Non-Small Cell Lung Cancer (NSCLC) than placebo taken with SBRT.
    • SBRT is a procedure where radiation is given to an exact location to destroy cancer cells in your tumor.
    • Placebo is a look alike product with no active ingredients. 
  • See if pembrolizumab helps patients live longer and helps patients have a better quality of life
  • Test the safety of the study drug pembrolizumab in patients with NSCLC after SBRT
  • See how well your body handles pembrolizumab compared to placebo with SBRT
  • See if the study drug helps patients live longer.
  • Condition: Non-squamous, non-small cell lung cancer
  • Study ID: NCT03924869
  • Sponsor: Merck Sharp & Dohme, Corp.
  • Location: The Moncton Hospital
  • Horizon Principal Investigator: Dr. Mahmoud Abdelsalam
  • To participate, call the research coordinator at: 506-857-5669 and refer to study file #100380

A Multi-centre Observational Study to Evaluate the Clinical Utility of Returning Genomic Aberration Results Using the Oncomine Precision Assay in Advanced or Metastatic Non-Small Cell Lung Cancer within the Exactis Network

Analysis of your tumor tissue is key to diagnose your type of cancer and to make a decision about the type of therapy that is most suitable for you. However, collecting sufficient tumor tissue is a considerable challenge in lung cancer patients, as many patients cannot undergo resection/biopsy (surgical procedures for tissue collection), due to risk of lung collapse and other contraindications.

We can now use a blood sample (called liquid biopsy) as a simple and non-invasive alternative to surgical biopsies. This blood sample can enable doctors to discover a range of information about the properties/particularities (molecular profile) of your tumor. In this study, a novel assay called Oncomine Precision Assay (OPA) developed by the company Thermo Fisher Scientific will be used to analyze the molecular profile of your cancer through your blood samples and possibly your tumor tissue.

  • Condition: Non-small cell lung cancer
  • Study ID: NCT04564079
  • Sponsor: Exactis Innovation
  • Location: The Moncton Hospital
  • Horizon Principal Investigator: Dr. Mahmoud Abdelsalam
  • To participate, call the research coordinator at: 506-857-5756 and refer to study file #101104

EA5163/S1709 INSIGNA:Testing the timing of immunotherapy alone or with chemotherapy as first line treatment and maintenance in non-small cell lung cancer

The purpose of this study is to compare the effects on you and your lung cancer of a new drug, pembrolizumab compared to other drugs which are commonly-used drugs to treat this disease. The study will compare any good and bad effects of using only the immunotherapy drug, pembrolizumab, alone first versus the combination of the immunotherapy drug, pembrolizumab, and chemotherapy. This study will also compare if continuing immunotherapy when the disease is growing after chemotherapy has begun is helpful.

  • Condition: Non-squamous, non-small cell lung cancer
  • Study ID: NCT03793179
  • Sponsor: National Cancer Institute
  • Location: Saint John Regional Hospital
  • Horizon Principal Investigator: Dr. James Michael
  • To participate, call the research coordinator at: 506-648-6890 and refer to study file #100629

CCTG BRC.8 Testing whether the use of brain scans alone instead of brain scans plus preventive brain radiation affects lifespan in patients with small cell lung cancer

The purpose of this study is to compare the effects of using brain MRIs alone versus brain MRIs plus PCI on the lifespan of patients with small cell lung cancer.

  • Condition: Lung small cell carcinoma
  • Study ID: NCT04155034
  • Sponsor: Southwest Oncology Group
  • Location: Saint John Regional Hospital
  • Horizon Principal Investigator: Dr. Farah Naz
  • To participate, call the research coordinator at: 506-648-6890 and refer to study file #100953

PICOMOLE LUNG: Analysis of volatile chemicals in the breath of lung cancer patients using infrared spectroscopy

The purpose of this study is to collect and analyze the volatile organic compounds (VOCs) of lung cancer patients and healthy individuals without lung cancer.  The breath sample analysis will allow for the identification of patterns of VOCs that are either over- or under-represented in patients with lung cancer when compared to "healthy" breath profiles using infrared spectroscopy.  The scientists think that the profile of volatile chemicals in the breath of lung cancer patients might be different from those individuals without lung cancer.

  • Condition: Lung cancer
  • Study ID: NCT03829319
  • Sponsor: Picomole, Inc.
  • Locations:
    • The Moncton Hospital
      • Horizon Principal Investigator: Dr. Mahmoud Abdelsalam
      • To participate, call the research coordinator at: 506-870-5756 and refer to study file #10171
    • Saint John Regional Hospital
      • Horizon Principal Investigator: Dr. Anthony Reiman
      • To participate, call the research coordinator at: 506-648-7852 and refer to study file #10170

ACRI LUNG 01: Development of liquid biopsy based test for lung cancer patient: Tumor diagnosis and treatment monitoring in a blood test

The goal of this research study is to enable the development of a new non-invasive method of diagnosis. This project involves collecting blood samples and tumors recovered after a biopsy or tumor resection (if applicable) from individuals diagnosed with lung cancer.

  • Condition: Lung cancer
  • Sponsor: Atlantic Cancer Research Institute
  • Location: The Moncton Hospital
  • Horizon Principal Investigator: Dr. Mahmoud Abdelsalam
  • To participate, call the research coordinator at: 506-870-5756 and refer to study file #101031

MELANOMA

POLARIS: An Open-Label, Randomized, Multicenter Trial of Encorafenib + Binimetinib Evaluating a Standard-dose and a High-dose Regimen in Patients With BRAFV600-mutant Melanoma Brain Metastasis

The purpose of this research study is to determine if high‑dose versus standard-dose regimens of encorafenib and binimetinib are safe and have positive effects in people who have melanoma with asymptomatic brain metastasis and also have been found by their doctor to have a mutated gene called BRAFV600.

  • Condition: Melanoma with brain metastasis
  • Study ID: NCT03911869
  • Sponsor: Pfizer
  • Location: Dr. Everett Chalmers Regional Hospital
  • Horizon Principal Investigator: Dr. Muhammed Saleem Raza
  • To participate, call the research coordinator at: 506-471-9924 and refer to study file #100353

KEYNOTE 695: A Multicenter Phase 2, Open-Label Trial of Intratumoral tavokinogene telseplasmid (tavo, pIL-12) plus Electroporation in Combination with Pembrolizumab in Patients with Stage III/IV Melanoma who are Progressing on either Pembrolizumab or Nivolumab Treatment

The purpose of this study is to find out what effects, good and/or bad, the combination of a type of gene therapy treatment called plasmid electroporation and pembrolizumab has on your cancer. 

  • Condition: Stage III/IV melanoma
  • Study ID: NCT03132675
  • Sponsor: OncoSec Medical Incorporated
  • Location: The Moncton Hospital
  • Horizon Principal Investigator: Dr. Mahmoud Abdelsalam
  • To participate, call the research coordinator at: 506-870-5669 and refer to study file #100632

PROSTATE CANCER

ARC-6: Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer

The purpose of Stage 1 (first part) of this study is to help the Sponsor understand whether an experimental medication, called AB928, that is not approved for use, is safe and effective in combination with other therapies for the potential treatment of mCRPC. "Experimental" means that the study medications being tested have not been approved by Heath Canada or any other local Regulatory/Health Authorities.

The purpose of Stage 2 (second part) of this study is to help the Sponsor understand whether experimental medication, AB928, works in combination with other medications to stop or slow tumor growth in patients with mCRPC. AB928 may be combined with other experimental treatments in both stages, known as AB680 and zimberelimab, or may be combined with medications that are approved by Health Canada and other government agencies to treat mCRPC.

  • Condition: Castration-resistant / androgen-resistant prostate cancer
  • Study ID: NCT04381832
  • Sponsor: Arcus Biosciences, Inc.
  • Location: The Moncton Hospital
  • Horizon Principal Investigator: Dr. Mahmoud Abdelsalam
  • To participate, call the research coordinator at: 506-870-5756 and refer to study file #100994

PEACE III: A randomized multicenter phase III trial comparing enzalutamide vs. a combination of Ra223 and enzalutamide in asymptomatic or mildly symptomatic castration resistant prostate cancer patients metastatic to bone

The main goal of this study is to determine whether the combination of radium-223 and enzalutamide achieves better activity than enzalutamide alone in patients with metastatic castration-resistant prostate cancer, and to verify the safety of the use of radium-223 and enzalutamide in combination.

  • Condition: Prostate cancer
  • Study ID: NCT02194842
  • Sponsor: European Organisation for Research and Treatment of Cancer
  • Location: Saint John Regional Hospital
  • Horizon Principal Investigator: Dr. Samantha Gray
  • To participate, call the research coordinator at: 506-648-6890 and refer to study file #100628

PRIME: A trial studying metformin's ability to prevent and treat metabolic complications from hormonal therapy

The purpose of this study is to compare the effects on you and your prostate cancer of the drug metformin,compared to the standard treatment (which is no extra treatment beyond that aimed at your cancer).

  • Condition: Prostate cancer
  • Study ID: NCT03031821
  • Sponsor: Canadian Urologic Oncology Group
  • Location: Saint John Regional Hospital
  • Horizon Principal Investigator: Dr. Holly Campbell
  • To participate, call the research coordinator at: 506-648-6890 and refer to study file #10114

CONTACT-02: A Phase 3, Randomized, Open-Label, Controlled Study of Cabozantinib (XL184) in Combination with Atezolizumab vs Second Novel Hormonal Therapy (NHT) in Subjects with Metastatic Castration-Resistant Prostate Cancer.

The purpose of this study is to find out whether cabozantinib in combination with atezolizumab is effective in treating prostate cancer compared with a second novel hormonal therapy (NHT).

  • Condition: Metastatic prostate cancer
  • Study ID: NCT04446117
  • Sponsor: Exelixis
  • Location: The Moncton Hospital
  • Horizon Principal Investigator: Dr. Mahmoud Abdelsalam
  • To participate, call the research coordinator at: 506-870-5756 and refer to study file #100933
Text Size:

Helpful Links